Vialox

What is Vialox?

Vialox (Pentapeptide-3) is a synthetic pentapeptide (GPRPA) sold by Pentapharm (now part of dsm-firmenich) as a topical cosmeceutical for reducing expression wrinkles. It is often marketed as inspired by Temple Pit Viper venom, but its sequence does not occur anywhere in waglerin-1, the 22-residue viper toxin it is usually linked to; the waglerin-1 mimic in Pentapharm's range is its sister ingredient Syn-Ake. The same molecule was first patented in 1990 by Behringwerke as a blocker of blood-clot formation, and the earliest cosmetic patent (2004) calls it 'curare-like'. Vialox acts as a competitive antagonist at the muscular nicotinic acetylcholine receptor (nAChR), blocking the signal that tells facial muscles to contract. A 71% drop in contractions one minute after adding it to cultured muscle cells circulates widely as a Pentapharm figure, but it appears in no retrievable primary document — not in either patent, not in the reviews that discuss Vialox, and not in any supplier datasheet still available. The only published version of that experiment is a 2004 patent testing the same molecule at 0.3% in a nerve-muscle co-culture, which found contraction frequency fell 69.75% at one minute and 60.75% at two hours. Pentapharm also reported that a cream containing 5% Vialox reduced wrinkle size by up to 49% and skin roughness by up to 47% after 28 days, but that study was never published and its number of volunteers is unknown. Unlike injectable Botox, Vialox is applied topically with gentler, partial muscle relaxation.

What Vialox Is Investigated For

Vialox is investigated as a topical cosmeceutical anti-wrinkle active described as a curare-like, postsynaptic nicotinic acetylcholine receptor antagonist to reduce dynamic expression wrinkles. The only efficacy figures are unpublished Pentapharm data, relayed through a 2013 patent application from another company and later reviews: up to 49% smaller wrinkles and 47% less skin roughness after 28 days of a cream containing 5% Vialox. A widely repeated 71% drop in contractions of cultured muscle cells after one minute has no retrievable primary document at all; the only published figure of that kind, 69.75% at one minute, comes from a 2004 patent. The number of volunteers, use of a placebo, and measurement method were never reported. The honest caveats are significant. Efficacy claims rest almost entirely on manufacturer-sponsored studies that have not been independently replicated in peer-reviewed trials, and the headline 49% figure sits at the high end of cosmetic peptide claims — real-world effects at typical product concentrations are substantially more variable. No published binding or electrophysiology study has tested Vialox at the human nicotinic receptor, and whether the pentapeptide actually reaches neuromuscular junctions in facial musculature at meaningful concentrations from topical application remains the central unresolved question. The 'natural Botox' marketing framing overstates magnitude — Phase 3 trials of injectable botulinum toxin report 4-week responder rates of roughly 71% to 95% depending on product and endpoint, and no study has compared any of them head-to-head with topical Vialox.

History & Discovery

Vialox was sold by Pentapharm, a Basel, Switzerland company, and was already in its patent-protected cosmetic actives range when DSM agreed to buy Pentapharm in July 2007; the business is now part of dsm-firmenich. The molecule is older than the brand, and older than that patent. Gly-Pro-Arg-Pro is the classic fibrin 'knob A' peptide, characterized in the peer-reviewed literature from 1984 onward as an inhibitor of fibrinogen aggregation. GPRPA-NH2 is the only fully worked example in a 1990 Behringwerke patent on peptide amides that prevent blood clotting, filed by Werner Stueber and Karl Fickenscher with a priority date of 8 May 1990; the application was later withdrawn and the family is now assigned to Siemens Healthcare Diagnostics. The molecule went on to be used as a fibrin-aggregation inhibitor in blood-test reagents. Cosmetic use was described in a patent filed in December 2004 by the Swiss company Labo Cosprophar AG — inventors Daniela Montanari and Manuela Guglielmo, granted 7 December 2010 and since expired for non-payment — which called the pentapeptide 'curare-like' and said it competes with acetylcholine for its receptor. That patent tested it in a nerve-muscle cell co-culture and in an uncontrolled 20-day questionnaire study in 40 women using a finished product named Botoina. Notably, the patent that actually ran the muscle experiments never mentions waglerin, snake venom, or Tropidolaemus wagleri anywhere. Many reviews and a 2013 patent application describe Vialox as a snake-venom or waglerin-1 fragment, but the GPRPA sequence does not occur in waglerin-1 — the waglerin-1 mimic in Pentapharm's range is Syn-Ake. The route by which that error became a citable fact is traceable in four steps. A 2013 US patent application from Syneuro LLC asserted in its background section, with no citation, that Vialox is 'a pentapeptide fragment of the neurotoxin waglerin-1'. A 2017 peer-reviewed review in the journal Cosmetics then repeated the snake-venom derivation and the 49%/47% wrinkle figures, citing that patent as its source. A widely cited 2020 review in Frontiers in Chemistry cited the 2017 review, as did at least one major research-chemical supplier's product page. By 2026 a cell-culture paper was stating the venom derivation as established fact. No step in the chain adds evidence; each adds authority. Vialox was positioned as a topical alternative to Botox for expression lines. Independent academic literature on it remains thin: a 2020 review noted that the only available efficacy data were provided by the manufacturer, and the two peer-reviewed papers since (2026) are computer-docking and cell-culture studies. Vialox no longer appears in dsm-firmenich's current skin bioactives list, which still includes Syn-Ake.

How It Works

When you frown or squint, nerves release acetylcholine to make facial muscles contract. Over years, these repeated contractions create permanent wrinkles. Vialox sits on the muscle's acetylcholine receptor like a key that fits but doesn't turn, blocking the real signal. The muscles partially relax, and the wrinkles they create soften and smooth out.

Vialox (H-Gly-Pro-Arg-Pro-Ala-NH2; amidated C-terminus; molecular weight 495.6) is a synthetic pentapeptide. Its sequence is not part of waglerin-1, and it cannot be an active fragment of it even in principle. Waglerin-1 is 22 residues, GGKPDLRPCHPPCHYIPRPKPR; GPRPA appears nowhere in that string. Structure-function work on the toxin showed that a fragment containing residues 6 to 22 was non-toxic, so bioactivity requires one or more of the first five residues — which are GGKPD, not GPRPA — and that replacing the two half-cystines with alanine also abolished toxicity, meaning the single intramolecular disulfide bond is essential. GPRPA contains no cysteine. The identical molecule was instead first described as a fibrin-polymerization inhibitor: Gly-Pro-Arg-Pro is the classic fibrin 'knob A' peptide characterized in the 1980s and 1990s, and a 1990 Behringwerke patent by Werner Stueber and Karl Fickenscher worked up GPRPA-NH2 specifically as a peptide amide that prevents clot formation, for pharmaceutical or diagnostic use. That patent mentions no cosmetic use, no wrinkles, and no acetylcholine receptor. It is claimed to act as a competitive antagonist at the muscle nicotinic acetylcholine receptor (nAChR), competing with acetylcholine for its binding site; its binding site and subunit selectivity have never been characterized. By occupying the acetylcholine binding site on the postsynaptic membrane, Vialox prevents sodium channel opening, blocks membrane depolarization, and inhibits muscle contraction. The in vitro figure usually quoted — 71% fewer contractions one minute after adding it to cultured muscle cells — traces to no retrievable primary source. The only published version of the test, a 2004 Labo Cosprophar patent, used a nerve-muscle co-culture and reported 69.75% fewer contractions after one minute and 60.75% after two hours at 0.3%. No binding assay, electrophysiology recording, or subunit-selectivity study of Vialox at any nicotinic receptor has ever been published, so 'competitive antagonist' remains an assertion carried forward from that patent rather than a measured property. Manufacturer in vivo figure, with an unpublished design: up to 49% smaller wrinkles and 47% less roughness after 28 days of a cream containing 5% Vialox. This postsynaptic mechanism is complementary to presynaptic approaches: Argireline and SNAP-8 inhibit SNARE complex assembly, while Pentapeptide-18 mimics enkephalins to reduce catecholamine release. Combining pre- and postsynaptic peptides targets multiple nodes of neuromuscular transmission.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Vialox:

• 01Independent, non-industry-funded human trials on Vialox specifically — the existing efficacy claims (49% wrinkle-depth reduction at 28 days) are dominated by Pentapharm/DSM-associated studies and have not been replicated in peer-reviewed independent trials.
• 02Direct head-to-head comparisons with botulinum toxin (the implicit comparator), Argireline, Syn-Ake, and Pentapeptide-18 at matched concentrations and durations.
• 03Real-world skin-penetration and target-site quantification — whether the pentapeptide actually reaches nAChRs in facial musculature in clinically meaningful concentrations from topical application is the central unresolved question.
• 04Basic pharmacology — there is no published binding, electrophysiology, or subunit-selectivity study of Vialox at human (or any) nicotinic receptors; the receptor-blocking claim rests on contraction counts in cultured cells.
• 05No registered clinical trials — ClinicalTrials.gov lists no studies of Vialox or pentapeptide-3, and the 28-day manufacturer study has never been published with its design, sample size, or controls.
• 06Wet-laboratory tests of the computer-predicted targets (SIRT-1, MMP-1/8/13) from 2025 and 2026 docking studies — none has been checked in skin cells or tissue.
• 07Ingredient identity — the EU CosIng definition of pentapeptide-3 lists isoleucine, which the marketed GPRPA sequence lacks, so label identity and purity across suppliers are unverified.
• 08Long-term human data — most published work spans 28-day windows; multi-month and multi-year continuous use has not been studied as a distinct safety or efficacy question.
• 09Whether stacking Vialox with Syn-Ake produces additive benefit or redundant nAChR occupancy — the marketing pitch is synergy, but mechanism overlap suggests redundancy is at least as likely.

Forms & Administration

Vialox is used topically in cosmeceutical formulations. No manufacturer use level is publicly documented; patent examples use 0.3% to 1% pentapeptide by weight, and the manufacturer's 28-day claim used a cream containing 5% Vialox without saying whether that meant pure peptide or a supplied preparation. Often combined with Argireline, Syn-Ake, and/or Matrixyl for multi-target anti-aging. Applied to clean skin, typically twice daily. No prescription required.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Vialox is a cosmetic ingredient, not a drug. It is not FDA-approved to treat or prevent any medical condition, and cosmetic claims permitted on labels are limited to appearance-related language. Do not inject cosmetic peptide products — there is no authorized injectable category for Vialox and documented infection risk exists for unlicensed injection of cosmetic peptides.

Timeline of Effects

Common Questions

Who Vialox Is NOT For

Drug & Supplement Interactions

Documented pharmacological drug interactions for topical Vialox are minimal. Systemic absorption from typical topical use is low enough that meaningful interaction with oral or injected medications is not expected. The practical interaction space is topical layering with other actives. Vialox is compatible with most cosmetic ingredients — niacinamide, hyaluronic acid, ceramides, and other peptides layer readily. Co-formulation with Argireline is common and marketed as synergistic on the rationale that pre- and postsynaptic mechanisms hit different points in the same neuromuscular cascade. Stacking with Syn-Ake is common but raises a redundancy question — both Vialox and Syn-Ake target the postsynaptic nAChR, so additive benefit is theoretically capped. Layering with matrikine peptides (Matrixyl, Syn-Coll) combines independent mechanisms. High-concentration L-ascorbic acid (vitamin C) is acidic enough that concurrent same-layer application can destabilize peptide actives and is typically used at a different time of day. Strong AHA/BHA exfoliation on the same evening as Vialox can reduce peptide activity at the surface and increase irritation, so spacing is sensible. There is no documented concern with oral medications, systemic hormones, or anticoagulants at the level of topical cosmetic exposure. Patients receiving botulinum toxin injection generally do not need to stop Vialox beforehand.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions